Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events
about
sameAs
Risk factors and in-hospital outcomes in stroke and myocardial infarction patientsThe Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicityImpact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromesEvidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary careA cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countriesImproving secondary prevention in coronary bypass patients: closing the audit loopPractising what is preached: the MINAP studyA randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240]Antiplatelet therapy in populations at high risk of atherothrombosisHow equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West EnglandSurvival trends among Danish patients undergoing coronary angiography for known or suspected ischaemic heart disease: a population based follow up study, 1992-2000.Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction.Long-term prognosis of symptomatic isolated middle cerebral artery disease in Korean stroke patients.Intensive insulin therapy in intensive care: an example of the struggle to implement evidence-based medicine.Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services studyA retrospective cohort study on lifestyle habits of cardiovascular patients: how informative are medical records?Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin.A randomized clinical trial of secondary prevention among women hospitalized with coronary heart diseaseStatin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.Randomised trials of secondary prevention programmes in coronary heart disease: systematic reviewStandardised pre-hospital care of acute myocardial infarction patients: MISSION! guidelines applied in practice.Transfusion practice in the intensive care unit: a 10-year analysis.Identifying factors associated with experiences of coronary heart disease patients receiving structured chronic care and counselling in European primary care.The effect of post-discharge educational intervention on patients in achieving objectives in modifiable risk factors six months after discharge following an episode of acute coronary syndrome, (CAM-2 Project): a randomized controlled trial.The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomised controlled trial.Controlled trial of effect of documented cardiovascular risk scores on prescribing.Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].Use of cholesterol-lowering therapy and related beliefs among middle-aged adults after myocardial infarctionQuality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study.Temporal trends of system of care for STEMI: insights from the Jakarta Cardiovascular Care Unit Network System.Participatory learning: a Swedish perspectiveCardiovascular disease: different strategies for primary and secondary prevention?Early and late mortality after myocardial infarction in men and women: prospective observational study.Predictors of the quality of cardiovascular prevention--a multilevel cross-sectional studyIndividualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006.Undertreatment of hypercholesterolaemia: a population-based studyRecent trends in (under)treatment of hypercholesterolaemia in the NetherlandsAliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
P2860
Q24792705-E87CA02A-0162-46EE-A4D4-2DA480EE4F8DQ24794251-C8E32C08-68B4-498B-B753-E379230ECA06Q28166985-D79D1B9F-9AE5-48F2-8B0E-56CA5C4AE166Q28193220-FF3F8383-40AE-4110-BF28-AE23B4F237B6Q28196488-20518D7D-959C-407C-9C69-D972193AF267Q28196568-6F1C72C8-65E9-4231-B5B8-977266C708D5Q28210679-49C82E1C-CB32-4CDB-B27A-423A0B5C9DF0Q28211003-8352B270-1334-4DD7-958D-40DE7ED4416FQ28218403-D32FAC2B-0DD1-466D-8193-F452123C58C8Q28218702-892EAC91-3662-49B0-91CB-B332585E9C01Q28221444-23792145-FA40-46F8-9644-5C6B1B8EE7C4Q30479375-A6E18BD8-8612-4E3D-8918-3F4EC6217061Q30555484-73A4BE08-7345-4FAE-8665-533D4D272810Q31040193-E355B625-E838-4AD9-9A17-839B99C9BE81Q33265480-0B83D412-29F6-4733-BF5F-D2C31C99AD08Q33352311-CC0C3F86-23F0-4F88-9BFA-F51177B4A603Q33425471-D6F146EC-EEFC-410F-8DA6-BF985BDD43E8Q33680229-91111CA5-A55A-4D05-924D-443107401391Q33829406-83735D8D-7A35-4E88-9B0D-4CFAE7D0E545Q33936187-BB6BF175-E63A-4232-95F0-11D421AA71D4Q33944137-7A1F72E8-247A-47DC-BFFB-0A97D32E3F63Q34135254-EC59D559-518E-44C5-9191-8B48FF9584F3Q34145971-A1EF45F2-A2BD-4FFF-8E64-F0E07D3C9E2EQ34353957-74CBEDC2-C59F-4753-B685-10BB6DA919DBQ34408135-C9D96474-6A34-4B9B-B571-D9DB98EA63C5Q34410047-2268D75D-9DA1-4414-B12C-B78EAC13F632Q34464013-61CC9BC0-C002-41AA-A4B2-3F281F5F50F8Q34599557-1CF5B995-F6B5-4471-B56E-83847366A5AFQ34742822-DE394CE1-B9C5-4EAA-A499-3C21FEF953C9Q34810990-9C94B0AA-4045-4BFC-BC9A-F7A2520344BBQ35092590-DF1B04A3-82B9-4FCA-8E04-6159233DF2A5Q35581947-30501A50-EC13-4789-A94B-0D9FFA7CA324Q35583003-D3026873-418A-4381-90D2-3BDAB25201CEQ35583730-19D3598C-558C-48E3-8A25-2F9E787FD818Q35625562-044F1B8D-2E14-443A-A9DF-D6B6C2FEC5E1Q35727675-5BD14EB4-D250-43A9-8786-44B5D58C52FAQ35762012-A872B4A2-837C-4C89-9D09-101B464159A4Q35825259-C26373D1-3E98-4863-AF12-E7B13314F230Q35826287-0AA9B2AE-98AC-4129-8BE3-74B3A7F8C698Q35827907-8222CD8A-5B7A-4190-BF28-240BA5BD44A5
P2860
Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical reality of coronary p ...... Intervention to Reduce Events
@ast
Clinical reality of coronary p ...... Intervention to Reduce Events
@en
Clinical reality of coronary p ...... Intervention to Reduce Events
@nl
type
label
Clinical reality of coronary p ...... Intervention to Reduce Events
@ast
Clinical reality of coronary p ...... Intervention to Reduce Events
@en
Clinical reality of coronary p ...... Intervention to Reduce Events
@nl
prefLabel
Clinical reality of coronary p ...... Intervention to Reduce Events
@ast
Clinical reality of coronary p ...... Intervention to Reduce Events
@en
Clinical reality of coronary p ...... Intervention to Reduce Events
@nl
P1433
P1476
Clinical reality of coronary p ...... Intervention to Reduce Events
@en
P304
P407
P577
2001-03-31T00:00:00Z